Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity (Q37900207)

25 August 2017

1 reference

title

Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity (English)

1 reference

25 August 2017

0 references

1 reference

Thanos Athanasiou

4

0 references

author name string

Harsha Prasada Lashkari

1

1 reference

25 August 2017

Srdjan Saso

2

1 reference

25 August 2017

Lucas Moreno

3

1 reference

25 August 2017

Stergios Zacharoulis

5

1 reference

25 August 2017

5 July 2011

1 reference

Journal of Neuro-Oncology

25 August 2017

1 reference

25 August 2017

105

1 reference

25 August 2017

2

1 reference

25 August 2017

135-147

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0657-7

25 August 2017

0 references

cites work

Weighing the benefits and risks of radiation therapy for low-grade glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide: realizing the promise and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

A note on graphical presentation of estimated odds ratios from several clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide in children with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Quality of life in low-grade glioma patients receiving temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Early metabolic responses in temozolomide treated low-grade glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide for recurrent low-grade spinal cord gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide in pediatric low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Current and future developments in the use of temozolomide for the treatment of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0657-7

Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.

21 January 2018

1 reference

12 December 2020

Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study

1 reference

12 December 2020

Phase I trial of temozolomide using an extended continuous oral schedule.

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

1 reference

12 December 2020

10.1007/S11060-011-0657-7

Identifiers

DOI

1 reference

25 August 2017

1 reference